Escherichia coli Nissle 1917 (Mutaflor)

E. coli Nissle 1917 is a probiotic strain that produces microcins and colicins, antimicrobial peptides that inhibit pathogenic bacteria in the gut. This strain enhances intestinal barrier function and modulates immune responses through toll-like receptor activation.

Origin & History

Escherichia coli Nissle 1917 is a non-pathogenic strain of E. coli isolated in 1917. It is produced through fermentation and used in probiotic supplements for gastrointestinal health.

Historical & Cultural Context

Discovered during World War I, Escherichia coli Nissle 1917 has been used in Europe for decades to manage gastrointestinal disorders.

Health Benefits

- Supports gut health by inhibiting pathogenic bacteria, promoting a balanced microbiome. This can lead to improved digestive function and reduced bloating. - Enhances immune response by stimulating the production of immunoglobulins, which helps protect against infections. - Reduces symptoms of IBS by modulating gut motility, providing relief from abdominal pain and discomfort. - Supports mental health by interacting with the gut-brain axis, potentially alleviating symptoms of anxiety and depression. - Promotes skin health by reducing systemic inflammation, leading to clearer, healthier skin. - Aids in nutrient absorption by maintaining a healthy gut lining, ensuring efficient uptake of vitamins and minerals. - Supports urinary tract health by preventing the colonization of harmful bacteria, reducing the risk of infections.

How It Works

E. coli Nissle 1917 produces microcins H47 and M, along with colicins Ia and Ib, which target pathogenic bacteria by disrupting their cell membranes. The strain activates toll-like receptors 2 and 4 on intestinal epithelial cells, triggering NF-κB signaling pathways that enhance antimicrobial peptide production. It also stimulates secretory IgA production and strengthens tight junctions through upregulation of claudin and occludin proteins.

Scientific Research

Clinical studies, including RCTs, have shown that Escherichia coli Nissle 1917 is effective in maintaining remission in ulcerative colitis and improving gut health.

Clinical Summary

Clinical trials involving 200-300 participants show E. coli Nissle 1917 reduces IBS symptom severity by 40-60% compared to placebo over 6-12 weeks. Studies demonstrate 65-85% remission rates in ulcerative colitis maintenance therapy, comparable to mesalazine. Randomized controlled trials indicate significant reductions in pathogenic bacteria counts and improved intestinal permeability markers. Evidence quality is moderate to high for digestive conditions but limited for immune benefits.

Nutritional Profile

Escherichia coli Nissle 1917 (EcN) is a probiotic bacterium, not a conventional food ingredient, so it does not contribute macronutrients (carbohydrates, fats, proteins) or micronutrients in meaningful dietary quantities at therapeutic doses. Key bioactive components include: (1) Lipopolysaccharides (LPS) in the outer membrane, which at low, controlled doses stimulate innate immune signaling via TLR4 pathways without inducing systemic inflammation; (2) Flagellin proteins that activate TLR5-mediated immune responses; (3) Short-chain fatty acid (SCFA) precursors — EcN ferments available substrates to produce acetate and formate, contributing indirectly to butyrate production by cross-feeding colonic bacteria; (4) Microcins (low-molecular-weight antimicrobial peptides, notably microcins M and H47) that competitively inhibit pathogenic Enterobacteriaceae; (5) Siderophores (aerobactin, enterobactin) involved in iron chelation, which reduce iron availability for competing pathogens; (6) Colanic acid and other exopolysaccharides in the capsule that promote biofilm formation and colonization resistance. Typical therapeutic dosage in commercial Mutaflor capsules is 2.5×10^8 to 25×10^9 CFU per capsule. Protein content of the bacterial cell mass is approximately 50–60% of dry weight (predominantly structural and enzymatic proteins), but this is not bioavailable in a nutritional sense at probiotic doses. Bioavailability note: The strain is acid-sensitive and Mutaflor uses an enteric-coated capsule to ensure gastric acid bypass, with viable delivery to the colon estimated at 10–40% of ingested CFU depending on gastrointestinal transit conditions.

Preparation & Dosage

The recommended dosage is typically one capsule per day. Consult a healthcare provider before use.

Synergy & Pairings

Lactobacillus acidophilus, Bifidobacterium bifidum, Saccharomyces boulardii

Safety & Interactions

E. coli Nissle 1917 is generally well-tolerated with mild side effects including temporary bloating or gas in 5-15% of users during initial weeks. It may interact with immunosuppressive medications by potentially reducing their effectiveness through immune stimulation. The strain is contraindicated in severely immunocompromised individuals and those with central venous catheters due to bacteremia risk. Safety during pregnancy and breastfeeding has not been established through clinical trials.